top of page
Search

World Orphan Drug Virtual Conference

  • Eamon Mulvaney
  • Aug 18, 2020
  • 1 min read

Updated: Mar 29, 2022

Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on NTP42 an antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension (PAH).


 
 
 
Small Logo Gray.jpg

© 2025 ATXA Therapeutics Ltd. All Rights Reserved.

  • LinkedIn
  • X
  • Facebook
  • YouTube

TERMS OF USE

PRIVACY POLICY

Company number: 561857

UCD Conway Institute,

University College Dublin,

Belfield, Dublin 4, Ireland

Tel: +353 (0)1 525 2829

Contact Us

bottom of page